Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05800366 |
|---|---|
| Brief Title: | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma |
| First Submitted : | March 22, 2023 |
| First Submitted that Met QC Criteria : | April 4, 2023 |
| First Posted : | April 5, 2023 |
| Last Update Submitted that Met QC Criteria : | February 22, 2024 |
| Last Update Posted : | February 23, 2024 |